Who we are
Worldwide experts from academia and industry endorsing Novadiscovery’s approach.
What we do
For streamlined target identification & secured proof of concept.
What we do
Clinical insights & strategy
A digital sandbox to optimize trial design and capture best responders.
How we do it
The WISE engine
To ensure full traceability from a simulation output back to each primary source and avoid the black box syndrome.
How we do it
The effect model
The result of decades of experience in clinical trials methodology, the Effect Model law has solved the main problem plaguing the development of in silico clinical trials: the paradigm of efficacy.
We’re constantly on the hunt for the most talented individuals in our industry. If you have a knack for the development of mathematical and computational models of biological systems or if you are a genius developer with a keen interest in working on a state-of-the-art platform, fill the application form.
PAGE 2018 Meeting: An in silico model of Hepatitis B virus predicts patients response to ENYO PHARMA’s drug candidate EYP001
NOVADISCOVERY presents first results from the in silico component of the exploratory clinical program initiated by ENYO Pharma on EYP001, a non-bile acid FXR receptor agonist currently in phase 1b trial for the treatment of chronic Hepatitis B.
June 7, 2018
Dr Riad KAHOUL, MD, PhD, biostatisticien and biomodelizer in Nova team, will give a talk at the 10th edition of the event organized by AFCRO
It is now important for the European Medicines Agency to recognize and integrate into its regulatory processes these new methods of in silico simulation and prediction.
June 19, 2018
François-Henri BOISSEL, CEO, will be the moderator fo the panel discussion on “In silico medicine” at the 37 ºC “Digitalising health” Life science Technology & Business Conference, Stavanger Forum, Norway
to accelerate the clinical development of drug candidate EYP001.
October 2, 2017
François-Henri BOISSEL introducing NOVA at Labiotech Refresh 2017, Berlin.
Specify the optimal duration which helps to obtain the target effect, the dose that has to be used to maximize this effect. In other words, it’s to help us do the operations that are done today by a rather theoretical approach.
With the help of in silico models we can integrate the right patients in clinical trials and reduce the size of these trials.